The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

This study has been completed.
Sponsor:
Collaborator:
University of Tampa
Information provided by (Responsible Party):
Metabolic Technologies Inc.
ClinicalTrials.gov Identifier:
NCT01508338
First received: January 9, 2012
Last updated: March 17, 2014
Last verified: March 2014

January 9, 2012
March 17, 2014
January 2012
October 2012   (final data collection date for primary outcome measure)
Increased muscle strength, force, and power after intense weight training [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Increased muscle strength, force and power after intense weight training [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01508338 on ClinicalTrials.gov Archive Site
Increased muscle hypertrophy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes
The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

The purpose of this study is to

  • determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle hypertrophy, body composition, strength, force, velocity, and peak power during loaded and unloaded vertical jumps.

Additionally, the study will determine if either supplementation protocol prevents the typical decay seen in performance following an overreaching cycle performed in the 9th and 10th weeks of the study.

Finally, the study will elucidate the mechanisms of action of supplementation on protein breakdown by analyzing serum indices of muscle damage (CK, LDH) and anabolic status (Testosterone:Cortisol ratio) as well as a urinary indicator of protein breakdown (3-methylhistidine).

We hypothesize that under these conditions that the supplementation protocols will augment skeletal muscle hypertrophy, strength, and power and that HMB will blunt increases in serum indices of muscle damage, and urinary indices of protein breakdown.

In a randomized and double blind study the subjects will consume either placebo supplements, HMB supplement, ATP supplement, or HMB plus ATP supplements for 12 weeks. While consuming the supplements the subjects will undergo an extensive resistance training program designed to train all major muscle groups. An additional overreaching training cycle during weeks 9 and 10 which will involve a high-volume, hypertrophy style training program.

Subject testing will consist of the following:

  • Strength and power at weeks 0, 1, 4, 8, 9, 10, and 12
  • Range of motion and muscle soreness at weeks 0, 1, 8, 9, and 10
  • Body composition and muscle assessments at weeks 0, 1, 4, 8, 9, 10, and 12
  • Body fat assessments at weeks 0, 4, 8, and 12
  • Blood biochemical measurements at weeks 0, 1, 4, 8, 9, 10, and 12
  • Urinary analysis for protein breakdown (3-methylhistidine) at 0, 1, 8, 9, and 10 weeks
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Healthy Experienced Weight Training Males
  • Dietary Supplement: Placebo
    An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
  • Dietary Supplement: HMB
    A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
  • Dietary Supplement: Peak ATP and HMB
    One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
  • Dietary Supplement: ATP
    One capsule containing 400 mg of Peak ATP will be taken daily in the morning for 12 weeks.
  • Placebo Comparator: Placebo
    Intervention: Dietary Supplement: Placebo
  • Experimental: HMB
    Intervention: Dietary Supplement: HMB
  • Experimental: ATP and HMB
    Intervention: Dietary Supplement: Peak ATP and HMB
  • Experimental: ATP
    Intervention: Dietary Supplement: ATP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
October 2012
October 2012   (final data collection date for primary outcome measure)

Subjects must meet all of the inclusion criteria to participate in the study.

  • Have 3 years minimum of free weight training experience
  • Can squat a minimum of 1.5 times their bodyweight
  • Can bench press a minimum equal to their bodyweight
  • Can deadlift a minimum of 1.5 times their bodyweight
  • Are free of musculoskeletal injuries
  • Have not taken creatine or HMB supplements for 6 weeks
  • Are not taking amino acid supplements
  • Are not using anabolic or catabolic hormones
  • Are not taking medications that may interfere with study measurements
  • Are not users of tobacco products

All candidates meeting any one of the exclusion criteria will not be enrolled into the study.

  • Do not have 3 years minimum of free weight training experience
  • Can not squat a minimum of 1.5 times their bodyweight
  • Can not bench press a minimum equal to their bodyweight
  • Can not deadlift a minimum of 1.5 times their bodyweight
  • Are not free of musculoskeletal injuries
  • Have not taken creatine or HMB supplements in the past 6 weeks
  • Are currently taking amino acid supplements
  • Are using anabolic or catabolic hormones
  • Are taking medications that may interfere with study measurements
  • Use of tobacco products
Male
18 Years to 30 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01508338
MTI2012-CS01
No
Metabolic Technologies Inc.
Metabolic Technologies Inc.
University of Tampa
Study Director: John A Rathmacher, PhD Metabolic Technologies Inc.
Metabolic Technologies Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP